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Background: The human immunodeficiency virus (HIV-1) exploits host proteins to complete its life cycle.
Genome-wide siRNA approaches suggested that host proteins affect HIV-1 replication. However, the results barely
overlapped. RING finger protein 39 (RNF39) has been identified from genome-wide association studies. However, its
function during HIV-1 replication remains unclear.
Methods and results: We investigated the relationship between common RNF39 genetic variants and HIV-1 viral
loads. The effect of RNF39 protein knockdown or overexpression on HIV-1 replication was then investigated in
different cell lines. Two genetic variants were associated with HIV-1 viral loads. Patients with the ht1-GG/GG haplotype
presented lower RNF39 expression levels and lower HIV-1 viral load. RNF39 knockdown inhibited HIV-1 expression.
Conclusions: RNF39 protein may be involved in HIV-1 replication as observed in genetic studies on patients with HIV-1
and in in vitro cell cultures.
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The human immunodeficiency virus (HIV-1) genome
encodes for 15 viral proteins and exploits host cellular
proteins to complete its life cycle [1,2], which includes
viral entry, uncoating, reverse transcription, nuclear
import, integration, transcription, translation, viral
assembly, and virus budding [3-6]. Because of the
complicated nature of the viral life cycle and restricted
encoded viral proteins, the function of host cellular
proteins associated with virus replication remains to be
confirmed. Genome-wide siRNA screening approaches
have been conducted to identify host cellular proteins that
affect HIV-1 replication [7-10]. However, little overlapping
was observed between these screening studies. This may
be due to diverse experimental conditions, including virus* Correspondence: jeron888@gmail.com; d0704@mail.cmuh.org.tw
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unless otherwise stated.strains, cell line usages, the delivery efficiency of siRNAs
or shRNA libraries, and the analysis of RNAi datasets.
Therefore, functional characterization of interesting genes
and their genetic-clinical correlations in patients with
HIV-1 are essential to elucidate the role of host cellular
proteins in HIV-1 replication.
Previous genome-wide association studies have mapped
to a region close to the ZNRD1 (zinc ribbon domain-
containing 1) and RING finger protein 39 (RNF39)
associated with HIV-1 disease progression [11,12]. We
have also showed that ZNRD1 genetic variants contribute
to HIV-1 clinical course in the Han Chinese population in
Taiwan and that ZNRD1 RNA interference-mediated
silencing inhibited HIV-1 replication in Jurkat cells [13].
RNF39 encodes a protein containing a specialized type of
SPRY domain in its C-terminal that determines viral
specificity and restriction potency [14]. It is located within
the major histocompatibility complex class I region on
chromosome 6. However, its biological function during
HIV-1 replication remains unclear.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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study between RNF39 common genetic variants and
HIV-1 viral loads in a Han Chinese cohort in Taiwan
and evaluated the role of RNF39 in HIV-1 replication.
Our results suggest that RNF39 common genetic variants
associate with HIV-1 plasma viral loads and may be
required for HIV-1 replication.Results
RNF39 genetic variants, rs3807032, rs3807033, and
related haplotypes, associate with HIV-1 viral load levels
To further investigate the role of RNF39 genetic variants
in virus replication in patients infected by HIV-1, plasma
HIV-1 viral load levels and RNF39 genotype data were
collected from a cohort of Han Chinese patients infected
with HIV-1 in Taiwan (Tables 1 and 2). The clinical
characteristics are summarized in Table 1. Three-hundred
and three patients infected with HIV-1 (87.3% of male
patients) were included in this study. The mean plasma
HIV-1 viral load (before antiretroviral therapy) was 4.0
(2.6–6.4) log10 copies/mL. The association between the
mean of all available plasma HIV-1 viral load measure-
ments and RNF39 single nucleotide polymorphism (SNP)
genotypes is presented in Table 2. There were significant
differences in mean HIV-1 viral load levels among infected
patients with RNF39 SNP genotypes rs3807032 and
rs3807033. For patients presenting the SNP rs3807032
GG and CG +CC genotypes, the mean log10 HIV-1 viral
load was 3.9 (2.6–6.4) and 4.2 (2.6–5.8), respectively
(p = 0.002). Similar HIV-1 viral loads were also observed
for patients presenting the rs3807033 GG and AG+AA
genotypes, respectively (p = 0.002). Next, the mean HIV-1
viral loads were compared among RNF39 haplotypes
(Table 3). A significant difference in viral loads was
observed (p = 0.006). Patients with the RNF39 ht1-GG/GG
haplotype presented lower viral loads than patients with
the ht2-GG/CA and ht3-CA/CA haplotypes (p = 0.006).Table 1 Baseline characteristics of patients with HIV-1 in
the Han Chinese population in Taiwan
Variable Taiwanese HIV-1
infected patients
No. of participants 303
Male,% 87.3
Mean age at HIV-1 positive (range), yearsa 37.0 (20.6–78.7)




aThe age at HIV-1 antibody positive means the age of the patient when
he/she was examined with the earliest HIV-1 antibody positive result. The
HIV-1 antibody positive results were obtained from the department of medical
and laboratory examination database at our hospital.
bThe HIV-1 viral load was measured in peripheral blood when the patient was
examined with the earliest HIV-1 antibody positive result. Any measurements
taken after the initiation of antiretroviral therapy were not used in
any analyses.To investigate the correlation between RNF39 haplotypes
and its expression levels, we measured RNF39 mRNA
levels by real-time quantitative polymerase chain reaction
(qPCR) in primary peripheral blood mononuclear cells
from patients. As shown in Figure 1, RNF39 expression
level was lower in patients with the ht1-GG/GG haplotype
than in patients with the ht2-GG/CA and ht3-CA/CA
haplotypes (p = 0.043).
RNF39 affects HIV-1 replication in HEK293T cells
To further investigate the role of RNF39 in HIV-1
replication, we used siRNA to knockdown RNF39
expression in 293 T cells [15] (Figure 2A,B). HIV-1
GFP reporter virus NL4-△G/P-EGFP was employed as
an indicator of viral replication. Cells were first trans-
fected with siRNAs targeting RNF39 (siRNF39) and
the knockdown effect was assessed by qPCR. siRNA-
transfected 293 T cells were then infected with NL4-
3△G/P-EGFP. As shown in Figure 2B, a significant dif-
ference was observed in the number of GFP positive cells
between the cells transfected with control siRNA (siNC)
and those transfected with siRNF39. The number of GFP-
expressing cells decreased to 65% (p = 0.021). Azidothymid-
ine (AZT)-treated 293 T cells were used as positive con-
trols; AZT treatment decreased HIV-1 infection to 53.2%.
Next, RNF39 role in HIV-1 infection was also confirmed
by overexpressing RNF39 cDNA (Figure 3A,B and C) in
293 T cells. 293 T cells were transiently transfected with
RNF39 cDNA expression plasmid (pRNF39) and pCMV
expression plasmid as a mock control (Figure 3A). Cells
were then infected with NL4-3△G/P-EGFP. As shown in
Figure 3B, the number of GFP positive cells infected with
NL4-3△G/P-EGFP was increased in pRNF39-transfected
cells compared with that in the control cells (137.9%
increase, p = 0.030).
The cDNA overexpression method was further used to
evaluate the effect of several proteins on HIV-1 infection
after RNF39 knockdown by siRNA. siRNF39-treated
293 T cells were transfected with expression plasmids,
including the pZNRD1, pRNF39, and pCMV plasmid.
Cells were then infected with NL4-3△G/P-EGFP. As shown
in Figure 3C, the number of GFP positive cells infected
with NL4-3△G/P-EGFP increased after overexpression of
RNF39 or ZNRD1 (188.7% for pRNF39 and 170.7% for
pZNDR1, p = 0.004).
RNF39 is also required for HIV-1 replication in Jurkat cells
We also investigated the role of RNF39 in HIV-1 and
HTLV-1 replication (Figure 4). Jurkat cells were transi-
ently transfected with siRNAs. siRNA-treated Jurkat cells
were then transfected with HIV-1 molecular clone
pNL4-3 or HTLV-1 molecular clone k30 (Figure 4A). As
shown in Figure 4B and Additional file 1: Figure S1, the
expression of the HIV-1 p55 and p24 viral proteins was
Table 2 Effects of RNF39 gene SNPs on plasma HIV-1 viral load in the Han Chinese Population in Taiwan
Gene Location Position SNP Genotype Taiwanese HIV-1 infected patients
Genotype frequency (No (%)) HIV-1 Viral Load (log10 copies/mL,
mean (interquartile range))a
p-valueb
RNF39 5′ near gene 30,043,779 SNP1 rs3807032 GG* 219 (72.3) 3.9 (2.6–6.4) 0.002*
CG + CC 74 (24.4) + 10 (3.3) 4.2 (2.6–5.8)
5′ near gene 30,043,955 SNP2 rs3807033 GG* 220 (72.6) 3.9 (2.6–6.4) 0.002*
AG + AA 73 (24.1) + 10 (3.3) 4.2 (2.6–5.8)
5′ near gene 30,044,388 SNP3 rs3132682 CC* 95 (31.4) 3.9 (2.6–5.3) 0.299
CG + GG 127 (41.9) + 81 (26.7) 4.0 (2.6–6.4)
5′ near gene 30,044,827 SNP4 rs3807035 GG* 202 (66.7) 3.9 (2.6–6.4) 0.034
AG + AA 89 (29.4) + 12 (4.0) 4.1 (2.6–5.8)
5′ near gene 30,044,914 SNP5 rs3807036 GG* 283 (93.4) 4.0 (2.6–6.4) 0.199
AG + AA 20 (6.6) + 0 (0.0) 3.7 (2.6–4.8)
5′ near gene 30,045,199 SNP6 rs1150735 GG* 159 (52.5) 3.9 (2.6–5.3) 0.837
AG + AA 114 (37.6) + 30 (9.9) 4.0 (2.6–6.4)
The asterisk and bold, emphasizing statistical significance at p < 0.0083 (0.05/6).
aThe HIV-1 viral load was measured in the peripheral blood when the patient was examined with the earliest HIV-1 antibody positive result. Any measurements
taken after the initiation of antiretroviral therapy were not used in any analyses.
bp-values were obtained using the unpaired Student’s t-test.
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was significantly decreased in the siRNF39-transfected
Jurkat cells compared with that in the control siNC.
Similarly, a reduction of HIV-1 p24 viral antigen
levels was observed in the culture supernatants from
siRNF39-transfected Jurkat cells compared with cul-
ture supernatants from the siNC-transfected cells
(Figure 4C). No significant difference was observed in
HTLV-1 p19 viral antigen levels in culture supernatants
from siRNF39-transfected Jurkat cells (Figure 4D). Taken
together, these results suggested that RNF39 is required
for HIV-1 replication in Jurkat cells, whereas it does not
affect HTLV-1 replication.
Discussion
In the present study, we first showed that plasma HIV-1
viral loads are associated with RNF39 genetic variants in
patients infected with HIV-1. Furthermore, we found an
association between RNF39 haplotypes and HIV-1 viral
loads. Patients with the RNF39 ht1-GG/GG haplotype
presented lower levels of HIV-1 viral load. Both SNPsTable 3 Effects of RNF39 haplotypes on plasma HIV-1 viral loa
Haplotypes (SNP1-SNP2/SNP1-SNP2) Genotype frequency (no
Ht1 (GG/GG, n (%)) 125 (73.5)
Ht2 (GG/CA, n (%)) 43 (25.3)
Ht3 (CA/CA, n (%)) 2 (1.2)
The asterisk and bold, emphasizing statistical significance at p < 0.017 (0.05/3).
SNP1, rs3807032; SNP2, rs3807033.
aThe HIV-1 viral load was measured in the peripheral blood when the patient was e
taken after the initiation of antiretroviral therapy were not used in any analyses.
bp-values were obtained using the unpaired Student’s t-test.are located in the 5′ regulatory region, which may affect
nascent mRNA production or protein expression,
thereby modulating HIV-1 production. Patients with the
ht1-GG/GG haplotype exhibited lower levels of RNF39
expression. Our results suggest that RNF39 expression
knockdown inhibits HIV-1 expression, suggesting that
RNF39 is required for viral replication. Genome-wide
association studies (GWASs) revealed that human
genetic variations, especially in genes located in the
MHC region are involved in the control of HIV viral
load, CD4 count, or the disease clinical course [11,16]. A
few studies revealed that human genetic variations,
especially genes located in the MHC region, close to
RNF39, were associated with the control of HIV viral
load, CD4 count, and/or the disease clinical course, but
the results were still inconsistent [11,12,16,17]. RNF39
SNPs are related to both disease progression and viral
load [11,16]. RNF39 SNPs have been associated with
CD4 T-cell count, but not with disease course [12,17].
We showed that RNF39 gene plays an important role in
HIV replication and its genetic variants are associatedd in the Han Chinese Population in Taiwan





xamined with the earliest HIV-1 antibody positive result. Any measurements
Figure 1 RNF39 mRNA expression levels in PBMCs between the
RNF39 haplotypes. RNF39 relative expression was detected by
qPCR, and its expression in individuals with the ht1-GG/GG haplotype
was compared with that in individuals with the ht2-GG/CA and
ht3-CA/CA haplotypes. The relative expression levels were expressed
as RNF39 mRNA/HPRT mRNA ratio.
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minants for host control of infection, based on SNPs,
still need to be confirmed among different populations,
followed by detailed genomic and functional analyses of
the associated region to verify putative SNPs.
By using RNA interference and complementation of
RNF39 protein expression, we showed that RNF39 host
cellular protein affects HIV-1 replication. These findings
are in accordance with the identification of host cellular
proteins that contribute to the HIV-1 life cycle [1,2].
Although Ballana et al. reported that RNF39 downregu-
lation by siRNA did not impair HIV-1 replication in
HeLa-derived cell lines [18], we used both lymphoid and
non-lymphoid cell lines to demonstrate that RNF39
actually affects HIV-1 replication. RNF39 antiviral mech-
anism might be associated with the presence of the
SPRY domain in RNF39 protein C-terminal [14]. This
SPRY domain determines viral specificity and restriction
potency, and is one of the major determinants for the
host tropism of HIV-1 and related retroviruses [19-21].
To our knowledge, this is the first study to demonstratea positive correlation between RNF39 and HIV-1 replica-
tion. Our results provide in vitro evidence regarding the
role of RNF39 host cellular protein in HIV-1 replication
and suggest that this protein may contribute to HIV-1 life
cycle. Future studies in primary T cells and macrophages
are warranted to confirm its function.
In conclusion, we provided further information that
RNF39 is a host cellular protein required for HIV-1
replication in vitro and its genetic variants are associated
with HIV-1 viral loads. Our findings emphasize the
importance of studying individuals with a range of genetic
backgrounds in HIV-1 infection research.Materials and methods
Patients
This study was an observational study. The patients
with HIV-1 were recruited from the Section of Infectious
Diseases, Department of Internal Medicine, China
Medical University Hospital, Taichung, Taiwan. Voluntary
participants provided written informed consent and agreed
to provide long-term follow-up clinical, epidemiological
data, plasma, and peripheral blood mononuclear cells
(PBMCs). Blood was collected by venipuncture. PBMCs
were isolated by Ficoll-Histopaque (Sigma Aldrich, Saint
Louis, MO, USA, 1077) density gradient centrifugation and
frozen until use. HIV-1-antibody-positive individuals were
recruited and HIV status was confirmed by quantitative
HIV-1 RNA measurement (Roche, Basel, Switzerland;
COBAS TaqMan HIV-1 assay v2.0).
HIV-1 viral loads were determined when the patient
was examined with the earliest HIV-1 antibody positive
result. Patients whose viral loads were measured after
the initiation of antiretroviral treatment were excluded
from the study. These patients with HIV-1 were (a)
naïve for antiretroviral treatment, (b) belonged to the
Han Chinese ethnic group, and (c) were willing to provide
blood samples for genotyping. The study was approved
by the Institutional Review Board of China Medical
University Hospital. All participants read and signed
informed consent documents.Detection of RNF39 genetic polymorphisms
RNF39 SNPs were selected from the NCBI SNP database
and HAPMAP website [13,22-24]. Selection criteria were a
minor allele frequency >5% in the Han Chinese population
and Hardy–Weinberg equilibrium (p > 0.05). A summary
of RNF39 gene SNPs information (location, position, rs
number, and genotype) is presented in Table 2. Briefly,
genomic DNA was extracted from PBMCs according
to standard protocols (Genomic DNA kit, Qiagen,
Limburg, Netherlands). SNPs were genotyped using a
custom-designed VeraCode GoldenGate Genotyping


























































Figure 2 RNF39 protein effects on HIV-1 replication in 293 T cells by using RNA interference assay. A. RNF39 mRNA downregulation by
RNA interference in 293 T cells. Relative RNF39 mRNA was quantified by qPCR. Values are normalized to those of siNC-transfected cells. Data
represent the mean ± SD of three independent experiments. B. Reduction of HIV-1 infection via RNF39 knockdown in 293 T cells. AZT-treated
293 T cells were used as a positive control for the reduction of HIV-1 infection.
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Illumina website (http://www.illumina.com/).
Real-time quantitative PCR
Total RNAs were isolated from PBMCs using the
RNeasy Mini kit (Qiagen). RNF39 mRNA relative
levels from individuals were measured by qPCR and
























































Figure 3 RNF39 protein effects on HIV-1 replication in 293 T cells as e
overexpression in 293 T cells by using the RNF39 cDNA vector under CMV
qPCR. Values are normalized to those of pCMV-transfected cells. Data repre
of HIV-1 infection via RNF39 overexpression in 293 T cells. C. Enrichment of
siRNF39-pRNF39-transfected 293 T cells.ProbeLibrary Assay Design Center, Roche). The rela-
tive expression levels were expressed as RNF39
mRNA/HPRT mRNA ratio (Figure 1). For human
genes, primers and DNA probes were commercially
designed and purchased (RNF39 gene, forward pri-
mer: 5′-agactgacagccgacctga-3′ and reverse primer:
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Figure 4 (See legend on next page.)
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Figure 4 RNF39 protein effects on HIV-1 replication in Jurkat cells as evaluated by RNA interference assay. A. Flowchart depicting siRNA
effect on the replication of retroviruses (HIV-1 molecular clone pNL4-3 and HTLV-1 molecular clone k30). B. Inhibition of HIV-1 replication by
RNF39 downregulation in Jurkat cells, measured using western blot analysis. C. Reduction of HIV-1 p24 antigen levels in culture supernatants from
siRNF39-transfected Jurkat cells compared with culture supernatants from siNC-transfected cells, measured using HIV-1 p24 ELISA. D. No
significant reduction of HTLV-1 p19 antigen levels was observed in culture supernatants from siRNAs-transfected Jurkat cells, measured
using HTLV-1 p19 ELISA.
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Genotypes were obtained by direct count, followed by
allele frequency calculations (Table 2). The unpaired
Student’s t-test was used for comparison between groups
(Tables 2 and 3). Lewontin’s D’ measure was used to
estimate the intermarker coefficient of linkage dis-
equilibrium (LD) of our patients with HIV-1 using
HAPLOVIEW software [24]. The LD confidence interval
was estimated using a resampling procedure and was used
to construct the haplotype blocks [26]. Haplotypes were
inferred from unphased genotype data by using the
Bayesian statistical method available in the program
Phase 2.1 [27-29]. All statistical analysis was performed
using SPSS (v12.0; IBM, Chicago, IL, USA) for Windows,
and graphs were generated using GraphPad Prism version
5.01 for Windows (GraphPad Software, San Diego,
California, USA).
Cells and recombinant virus
293 T cells (ATCC, Manassas, VA, USA; accession no.
CRL-11268) were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 100 U/mL penicillin,
100 U/mL streptomycin, and 2 mM L-glutamine (Gibco).
Jurkat cells (ATCC; accession number TIB-152) were
grown in RPMI-1640 medium supplemented with 10%
FBS and 100 U/mL penicillin, 100 U/mL streptomycin,
and 2 mM L-glutamine.
HIV-1 pseudotyped virus NL4-3△G/P-EGFP was
produced from 293 T cells as previously described
[15]. Briefly, cells were cotransfected with three package
vectors including pCMV△R8.2 (the package vector), pMD.
G (VSV-G expression vector), and pNL4-3:△G/P-EGFP
(HIV-1 molecular clone NL4-3 strain with EGFP reporter
gene, without viral gag and pol genes). After 48 h of
incubation, viruses were collected from the culture
supernatant and titrated on 293 T cells based on GFP
expression. Cells were infected with NL4-3△G/P-EGFP
(multiplicity of infection (moi) = 5) in the presence of
6 μg/mL polybrene (Sigma).
The HIV-1 (pNL4-3) and HTLV-1 k30 molecular
clones and the viral Tax gene clone were obtained
from the NIH AIDS Research and Reference Reagent
Program [30-32]. All media were supplemented with
100 U/mL penicillin, 100 U/mL streptomycin, and
2 mM L-glutamine.Drug and short interfering RNAs
AZT was commercially obtained (Sigma). Short Interfer-
ing RNAs (siRNAs) targeting transcripts for RNF39
(siRNF39: GACUGAGACUCUGGUUGAAGAGAGA)
and the non-targeting siRNA control (siNC) were
purchased from Invitrogen (Carlsbad, CA, USA).
siRNA or cDNA plasmid transfection
For 293 T cells, cells (2 × 105) were seeded in 24-well plates
and cultured for 24 h. siRNAs or cDNA plasmid targeting
RNF39 (NM_025236) (Figure 2A,B and Figure 3A,B and C)
were mixed with Roche X-tremeGENE Transfection
Reagent (Roche) in serum-free medium (OPTI-MEM I,
Invitrogen) following the manufacturer’s recommendations.
siRNA or cDNA plasmid-transfected 293 T cells were then
infected with NL4-3△G/P-EGFP (moi = 5) in the presence
of 6 μg/mL polybrene (Sigma) for 36 h. After infection, cells
were used for the quantification of EGFP expression by flow
cytometry.
For Jurkat cells, cells (2 × 105) were seeded in 24-well
plates and cultured for 24 h. siRNAs targeting RNF39
(NM_025236) (Figure 4) were transfected using Amaxa
Nucleofector Technology (Lonza, Basel, Switzerland)
following the manufacturer’s recommendations. Cells
were then recovered and seeded in prewarmed 24-well
plates. After 48 h incubation, Jurkat cells were transfected
with pNL4-3 or HTLV-1 molecular clone k30 and incu-
bated for another 36 h. Cells were then used for HIV-1
western blot analysis (Figure 4B), HIV-1 p24 antigen
enzyme-linked immunosorbent assay (ELISA) (Figure 4C),
and HTLV-1 p19 antigen ELISA (Figure 4D).
Reagents and western blot
The anti-HIV-1 antibody was obtained from the NIH
AIDS Research and Reference Reagent Program. The
anti-beta tubulin antibody was obtained from GeneTex
(GeneTex, Irvine, CA, USA; GTX101279). The HTLV-1
p19 ELISA kit and anti-p19 antibody were from Zepto-
metrix (Buffalo, NY, USA). The experimental protocol
for western blot was previously described [33,34]. Briefly,
cells were harvested, washed, and lysed in lysis buffer
(50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 0.1% SDS) supplemented
with protease inhibitor cocktail (Roche). The lysates
were resolved by 12% SDS-PAGE and transferred to
polyvinylidene fluoride membranes (Millipore, Billerica,
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antibodies overnight at 4°C, and then incubated with
alkaline phosphatase-conjugated secondary antibodies
(Sigma). Signals were visualized using chemiluminescence
following the manufacturer’s protocol (Chemicon, Billerica,
MA, USA). Band intensities were quantified using ImageJ
software.Additional file
Additional file 1: Figure S1. Inhibition of HIV-1 replication by RNF39
RNA interference-mediated silencing in Jurkat cells. Upper diagram:
relative HIV-1 p55 viral protein levels were monitored by band intensities
quantified using ImageJ software. Lower diagram: relative HIV-1 p24 viral
protein levels were monitored by band intensities quantified using
ImageJ sofware. Relative HIV-1 viral protein levels were calculated as a
ratio of the band intensities of siRNF39-treated cells to siNC-treated cells.
The western blot data was shown in Figure 4B and these results
represents mean ± for three independent experiments.Competing interests
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